Drugs in the pipeline for the Obesity market

Journal of Diabetes Science and Technology

Volumn 2, Issue 5, 2008, Pages 913-918

  Klonoff, David C ^a   Greenway, Frank ^b  

^a DIABETES RESEARCH INSTITUTE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

5 hydroxytryptamine; Cannabinoid; Incretin; Obesity; Peptide YY; Pharmacologic

Indexed keywords

EID: 84874677540     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200525     Document Type: Article

References (50)

1. NIH Consensus Development Conference Statement. Health implications of obesity. Ann Internal Med. 1985;103:1973-7.
2. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007;298(17):2028-37.
3. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, MD: NIH Publication No. 98-4083;1998.
4. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Metaanalysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-46.
5. Harrold JA, Halford JC. The hypothalamus and obesity. Recent Patents CNS Drug Discov. 2006;1(3):305-14.
6. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res. 2008;36:135-45.
7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31(1):53-65.
8. Krotkiewski M. Thyroid hormones and treatment of obesity. Int J Obes Relat Metab Disord. 2000;24 Suppl 2:S116-9.
9. Sawa M, Harada H. Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists. Curr Med Chem. 2006;13(1):25-37.
10. van Baak MA, Hul GB, Toubro S, Astrup A, Gottesdiener KM, De Smet M, Saris WH. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther. 2002;71(4):272-9.
11. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, Astrup A. Effect of a 28-d treatment with L-796568, a novel beta (3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002;76(4):780-8.
12. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev. 2001;2(3):199-211.
13. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289(12):1537-45.
14. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord. 1992;16(4):269-77.
15. Silverstone T. Appetite suppressants. A review. Drugs. 1992;43(6):820-36.
16. Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55.
17. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag. 2007;3(6):817-21.
18. http://www.mmlli.com/whatisalli.aspx [cited 2008 Mar. 23].
19. Parsons WB Jr. Controlled-release diethylpropion hydrochloride used in a program for weight reduction. Clin Ther. 1981;3(5):329-35
20. Inoue S, Egawa M, Satoh S, Saito M, Suzuki H, Kumahara Y, Abe M, Kumagai A, Goto Y, Shizume K, et al. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am J Clin Nutr. 1992;55(1 Suppl):199S-202S.
21. Douglas JG, Munro JF. Drug treatment and obesity. Pharmacol Ther. 1982;18(3):351-73.
22. Craddock D. Anorectic drugs: use in general practice. Drugs. 1976;11(5):378-93.
23. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ. 2007;335(7631):1194-9.
24. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12(8):1197-211.
25. Stunkard AJ, Allison KC, Lundgren JD, Martino NS, Heo M, Etemad B, O'Reardon JP. A paradigm for facilitating pharmacotherapy at a distance: sertraline treatment of the night eating syndrome. J Clin Psychiatry. 2006;67(10):1568-72.
26. Hermansen K, Mortensen LS. Body weight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127-42.
27. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-86.
28. Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007;293(2):E620-7.
29. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet. 2007;370(9600):1706-13.
30. Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol. 2008;48(4):418-27.
31. Lange JH, Kruse CG. Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists Drug Discov Today. 2005;10(10):693-702.
32. http://clinicaltrials. Qov/ct2/show/NCT00598286 [cited 2008 Mar. 23].
33. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shama H, Smith B, Chalmers D, Behan D. Lorcaserin, a novel selective human 5-HT2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577-87.
34. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv. 2005;5(5):282-91.
35. http://clinicaltrials.gov/ct2/show/NCT00603902 [cited 2008 Mar. 23].
36. Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007;31(3):494-9.
37. http://www.novonordisk.com/include/asp/exe news attachment.pdf?sAttac hmentGUID=dbcle5bd-ac70-49c6-a08d-3ea3224f95dl [cited 2008 Mar. 23].
38. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res. 1997;5(6):578-86.
39. http://files.shareholder.com/downloads/OREXl242254071x0x138524/ 9adfbf40-106f-4e0e-9f70-55b9cel6507f/Contrave-Poster-NAASO-Final.pdf [cited 2008 Mar. 23].
40. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week doubleblind, placebo-controlled trial. Obes Res. 2002;10(7):633-41.
41. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002;26(6):713-28.
42. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289(14):1820-5.
43. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8):1226-9.
44. Fujioka K, Greenway F, Cowley M, Guttadauria M, Robinson J, Landbloom R, Tollefson G. The 24 week experience with a combination sustained release product of zonisamide and bupropion: evidence of an encouraging benefit: risk profile. Obesity. 2007(suppl.):A85.
45. http://clinicaltrials. Qov/ct2/show/NCT00518466 [cited 2008 Mar. 23].
46. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A; OBD-202 Study Group. A randomized, double-blind, placebocontrolled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30(6):1480-6.
47. http://www.biospace.com/news story.aspx?NewsEntityId=77600 [cited 2008 Apr. 7].
48. Stoeckel LE, Weller RE, Giddings M, Cox JE. Peptide YY levels are associated with appetite suppression in response to long-chain fatty acids. Physiol Behav. 2008;93(1-2):289-95.
49. Beglinger C, Degen L. Gastrointestinal satiety signals in humans-physiologic roles for GLP-1 and PYY? Physiol Behav. 2006;89(4):460-4.
50. Rivera G, Bocanegra-García V, Galiano S, Cirauqui N, Ceras J, Pérez S, Aldana I, Monge A. Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr Med Chem. 2008;15(10):1025-43.